Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a US biotechnology company. It develops small-molecule drugs, gene-editing-based therapies and cell therapies for serious diseases. Its shares trade on Nasdaq under the ticker VRTX.

The company's commercial foundation is its CFTR modulator drugs, which target the underlying cause of cystic fibrosis. As part of its strategy of expanding beyond this area, it co-developed Casgevy, based on CRISPR gene-editing technology, for sickle cell disease and beta thalassemia, and it has also brought a non-opioid painkiller for acute pain to market. Its research pipeline includes programs such as cell therapies for kidney diseases and insulin-dependent diabetes.

For biotech stocks, clinical trial data, regulatory approval decisions, reimbursement negotiations and the dependence of income on a single disease area are watched. The VRTX page on Lzzo.com shows the price in US dollars; Turkish lira, euro and pound sterling options, a historical price chart, technical indicators, the data source and the time of the update are also available on the page.